Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
-
A decrease in lactate concentration in
2024-04-07
A decrease in lactate concentration in the incubation medium was observed in samples treated with heparin and 2′,5′-dideoxyadenosine compared with the control (0.05; Fig. 2B). Discussion In the present study we compared the oxidative metabolism and intracellular signals of heparin, the glycosami
-
Patients with ADA SCID may experience autoimmune
2024-04-07
Patients with ADA-SCID may experience autoimmune AEs after SCT (and/or during ERT) that are thought to be related to immune dysregulation prior to achieving complete immune reconstitution. The more common autoimmune manifestations include hemolytic anemia, hypothyroidism, and immune thrombocytopenia
-
br Funding br Introduction l Dihydroxyphenylalanine l DOPA i
2024-04-03
Funding Introduction l-3,4-Dihydroxyphenylalanine (l-DOPA) is the gold-standard treatment for the motor symptoms of Parkinson's disease (PD); however, its chronic use induces severe motor complications that eventually limit its long-term efficacy (Bastide et al., 2015). The most disabling side
-
Taken together BRP represents a novel chemotype of LT
2024-04-03
Taken together, BRP-187 represents a novel chemotype of LT biosynthesis inhibitors with outstanding potency in human PMNL and monocytes activated under pathophysiological relevant conditions and with effectiveness in vivo. Using the PLA that visualizes the in situ interaction between 5-LO and FLAP i
-
HCC aetiology is multifactorial and the disease
2024-04-03
HCC aetiology is multifactorial and the disease is often preceded by other conditions including liver fibrosis and cirrhosis that are associated with HCV, HBV, alcoholic and non-alcoholic hepatitis. The discovery of new therapeutic targets will require a greater understanding of the pathogenic mecha
-
NGB 2904 synthesis br Conclusions br Author declaration br A
2024-04-03
Conclusions Author declaration Acknowledgements Introduction ASK1 scaffolding proteins ASK1 adaptor proteins Conclusions Scaffolding and adaptor proteins can coordinate the specific activation of a MAP3K-MAP2K-MAPK pathway in response to various stimuli. For example, both NGB 29
-
It remains unclear to what extent UCP and
2024-04-03
It remains unclear to what extent UCP2 and UCP3 are subject to the same acute molecular regulation as UCP1 (and the extent to which they share the same mechanism of uncoupling). Although they lack sequence homology in a matrix-localised region reportedly critical for fatty RN 1734 activation of UCP
-
Glycosylphosphatidylinositol GPI cell wall anchor
2024-04-03
Glycosylphosphatidylinositol (GPI) pexidartinib anchor synthesis pathway is another promising antifungal target. Novel inhibitors of Gwt1 and Mcd4, two enzymes in the GPI anchor pathway were identified by the chemical-genomics-based screening platform CaFT (Candida albicans fitness test) [89]. Scre
-
br Prostate cancer and resistance to AR targeting
2024-04-03
Prostate cancer and resistance to AR targeting treatment The AR plays a pivotal role in the development, differentiation, homeostasis and secretory function of the normal prostate (Wilson, 2011). The AR is also a key player in many phases of prostate carcinogenesis (Huggins et al., 1941, Scher an
-
To date attention has been directed towards new molecular
2024-04-03
To date, attention has been directed towards new molecular targets in luminal phenotype (ER-positive), such as CDK4/6 and, to a lesser extent, androgen receptor (AR) pathways [8]. While the role of CDK4/6 has been elucidated and their inhibitors have shown a benefit in luminal BC, the role of AR in
-
All desired compounds with a carboxylic acid
2024-04-02
All desired compounds with a carboxylic ISRIB synthesis substituent at N1 position of the quinoxalinone scaffold and a variety of aromatic substituents at C3 position were obtained by the syntheses starting from methoxy-substituted 3-chloro-quinoxalin-2(1)-ones () prepared as previously. As shown i
-
br Materials and method br Result and discussion br Conclusi
2024-04-02
Materials and method Result and discussion Conclusion Acknowledgments This work is partly supported by the University Research Committee (URC) of the Senate of The Federal University of Technology, Akure. The authors thanked IFS for the funds (F/4449 1F and F/4449-2F) used to purchase th
-
Subsequently Palvimaki et al corroborated
2024-04-02
Subsequently, Palvimaki et al. (1999) corroborated Ni and Miledi's study by demonstrating that treatment with fluoxetine leads to 43% occupancy of the 5-HT2C receptors. Moreover, the affinity of fluoxetine for 5HT2C receptors (Ki 65 nM) is close to its affinity for 5-HT transporters (Ki 33 nM) (Ni a
-
Adenosine A A agonists have been shown
2024-04-02
Adenosine A2A agonists have been shown to significantly reduce albuminuria in diabetic mice as well as plasma creatinine [24]. Proteinuria was greater in diabetic A2A knock-out (KO) mice than diabetic wild type (WT) mice [24]. Consistent with these findings, our laboratory initially found that prote
-
br Actin at presynapses br Conclusion Thanks to
2024-04-02
Actin at presynapses Conclusion Thanks to the recent discovery of rings, hotspots and trails, axonal Finasteride is back in the spotlight. These are exiting times for neuronal cell biologists armed with constantly improving labeling and imaging techniques to observe, quantify and perturb these
15363 records 144/1025 page Previous Next First page 上5页 141142143144145 下5页 Last page